Nanomedicines for Brain Targeting: A Patent Review | Bentham Science
Generic placeholder image

Recent Patents on Nanomedicine

Editor-in-Chief

ISSN (Print): 1877-9123
ISSN (Online): 1877-9131

Nanomedicines for Brain Targeting: A Patent Review

Author(s): Shadabul Haque, Shadab Md, Md Intekhab Alam, Jasjeet Kaur Sahni, Javed Ali and Sanjula Baboota

Volume 1, Issue 2, 2011

Page: [149 - 161] Pages: 13

DOI: 10.2174/1877912311101020149

Price: $65

Open Access Journals Promotions 2
Abstract

For more than 30 years, extensive efforts have been made to enhance the delivery of therapeutic molecules to the CNS as they have limited access because of blood brain barriers (BBB), enzymatic barriers and multiple endogenous transporters. Various strategies have been developed to transfer the therapeutic molecules across the vascular barriers of the CNS. Nanomedicine based approaches have risen tremendously over the last few years. These systems have many advantages over the conventional formulations, such as the possibility of bypassing the BBB in a non-invasive manner, the possibility of being structurally modified to modulate the biopharmaceutical properties of the encapsulated molecules and having structures made up of biocompatible and biodegradable materials. The present review focuses on the recent patents on nanomedicine based approaches like liposomes, nanoparticles, dendrimers and nanoemulsions for treating CNS diseases which would give an insight to the researchers, academia and industrialist.

Keywords: Nanomedicine, Brain targeting, CNS disorders, Nanoparticles, Dendrimers, blood brain barriers, multiple endogenous transporters, enzymatic barriers, CNS diseases, nanoemulsions, cerebrovasculature barrier, depression, insomnia, drug delivery, schizophrenia, nanocapsules


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy